Bio-View Ltd

Equities

BIOV

IL0010960495

Advanced Medical Equipment & Technology

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:05 2026-02-18 am EST			5-day change	1st Jan Change
16.70 ^ILa	0.00%		-2.91%	-

Dec. 30	An undisclosed buyer signed share sale agreement to acquire 20.97% stake in Bio-View Ltd from Emmanuel Gill for ILS 6.1 million.	CI
25-08-25	Bio-View Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI

An undisclosed buyer signed share sale agreement to acquire 20.97% stake in Bio-View Ltd from Emmanuel Gill for ILS 6.1 million.

Published on 12/30/2025

S&P Capital IQ

BIO-VIEW LTD

0.00%

ISRAEL TA 35 (TRG)

+0.87%

An undisclosed buyer signed share sale agreement to acquire 20.97% stake in Bio-View Ltd (TASE:BIOV) from Emmanuel Gill for ILS 6.1 million on December 30, 2025. A cash consideration of ILS 6.1 million will be paid for 27.751224 million shares.

The expected completion of the transaction is in 12 months.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	BIO-VIEW LTD	16.70ILa	0.00%	-2.91%	7.22M
	ISRAEL TA 35 (TRG)	4,232.65PTS	+0.87%	+1.74%	-

Latest news about Bio-View Ltd

Dec. 30	An undisclosed buyer signed share sale agreement to acquire 20.97% stake in Bio-View Ltd from Emmanuel Gill for ILS 6.1 million.	CI
25-08-25	Bio-View Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-03-23	Bio-View Ltd Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-12-18	Bioview Ltd. Presents Promising Results from Their Joint Liquid Biopsy Development Project	CI
24-08-19	Bio-View Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-08-18	Bio-View Ltd announces an Equity Buyback for ILS 0.7 million worth of its shares.	CI
24-08-17	Bio-View Ltd authorizes a Buyback Plan.	CI
24-03-27	Bio-View Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-27	Bio-View Ltd announces an Equity Buyback for ILS 0.7 million worth of its shares.	CI
24-03-26	Bio-View Ltd authorizes a Buyback Plan.	CI
23-08-22	Tranche Update on Bio-View Ltd's Equity Buyback Plan announced on March 27, 2023.	CI
23-08-20	Bio-View Ltd's Equity Buyback announced on March 27, 2023 has closed with 247,356 shares, representing 1.79% for ILS 0.87 million.	CI
23-08-14	Bio-View Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-03-27	Bio-View Ltd announces an Equity Buyback for ILS 0.87 million worth of its shares.	CI
23-03-27	Tranche Update on Bio-View Ltd's Equity Buyback Plan announced on November 30, 2022.	CI

Chart Bio-View Ltd

Duration

Period

BIOV: Dynamic Chart

Company Profile

Bio View Ltd is an Israel-based laboratory equipment developer. The Company manufactures and assembles, markets and services an automated cell diagnostic system for use in cytology, cytogenetic, hematology and pathology laboratories. The workstation is called Duet, which provides automated detection, classification, analysis, and counting of cells for diagnosis and study. Additionally, Duet provides a method to analyze both the morphology and the genetic content of the same cell. The Company has applications in Cancer diagnosis and follow-up of minimal-residual disease (MRD); in pre-natal and post-natal Cytogenetic analyses in the analysis of sperm cells and rare-cell detection (RCD). In 2005, the Company introduced two new scanning workstations: the ALLEGRO, for automated scanning of Fluorescence in-situ Hybridization (FISH) probes without Brightfield scanning, and the ACCORD, for the semi-automated imaging of FISH for breast cancer (Her-2/Neu) and for FISH on tissue.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement and Estimates

More financial data